MedTrace Logo

Metformin Treatment in Progressive Multiple Sclerosis

NCT05349474 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-07-22

No results posted yet for this study

Summary

The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

Conditions

Interventions

DRUG

Metformin 500 Mg Oral Tablet, up to 4 tablets a day

Metformin 500 mg oral tablets to be titrated to 2000 mg/day divided over two doses or maximum tolerated dose

DRUG

Placebo oral tablet identical to metformin, up to 4 tablets a day

Placebo tablets identical to metformin tablets. To be titrated to four tablets divded over two doses or maximum tolerated dose

Sponsors & Collaborators

Principal Investigators

  • Kevin R Patel, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-26
Primary Completion
2025-05-30
Completion
2025-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05349474 on ClinicalTrials.gov